

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cryofocus Medtech (Shanghai) Co., Ltd.

康豐生物科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6922)

POLL RESULTS OF THE 2022 ANNUAL GENERAL MEETING HELD ON JUNE 16, 2023; AND APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is pleased to announce that all the proposed resolutions as set out in the Notice of the AGM were duly passed by the Shareholders by way of poll at the AGM.

Reference is made to the notice (the “**Notice of the AGM**”) and the circular (the “**Circular**”) of the AGM of Cryofocus Medtech (Shanghai) Co., Ltd. (the “**Company**”) both dated April 26, 2023. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The AGM was convened at 10:00 a.m. on Friday, June 16, 2023 at 3rd Floor, Building 25, Lane 3399, Kangxin Road, Pudong New Area, Shanghai, the PRC. The AGM was convened by the Board in accordance with the Company Law of the PRC and the Articles of Association, and was chaired by Mr. ZHU Jun, an executive Director and the general manager of the Company.

ATTENDANCE AT THE AGM

As at the date of the AGM, the total number of issued Shares was 239,110,000 Shares, comprising 114,096,598 H Shares and 125,013,402 Unlisted Shares. The holders of all such Shares were entitled to attend and vote for or against all the resolutions proposed at the AGM. Shareholders holding an aggregate of 210,156,254 Shares (comprising 89,486,047 H Shares and 120,670,207 Unlisted Shares), representing approximately 87.89% of the total issued Shares, attended the AGM either in person or by proxy.

To the best knowledge, information and belief of the Company: (1) there were no Shares entitling the Shareholders to attend and abstain from voting in favor of the resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules; (2) no Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the AGM; and (3) no Shareholder has stated his/her/its intention to vote against or to abstain from voting on any of the resolutions proposed at the AGM. There were no Shares actually voted but excluded from calculating the poll results of the resolutions proposed at the AGM.

All Directors, namely Mr. LI Kejian, Mr. ZHU Jun, Mr. LV Shiwen, Mr. ZHAO Chunsheng, Dr. GAO Dayong, Mr. LIANG Hsien Tse Joseph, Dr. QIN Zheng and Dr. HU Henan, attended the AGM either in person or through electronic means.

POLL RESULTS OF THE AGM

The Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, and the Company acted as the scrutineers at the AGM for the purpose of vote-taking.

At the AGM, all the proposed resolutions as set out in the Notice of the AGM were taken by way of poll. The poll results in respect of the resolutions proposed at the AGM are as follows:

Ordinary Resolutions		Number of Votes (Approximate % of the Total Number of Votes Cast)		
		For	Against	Abstain
1.	To consider and approve the work report of the Board for 2022.	210,156,244 (100%)	0 (0%)	0 (-)
2.	To consider and approve the work report of the Board of Supervisors for 2022.	210,156,244 (100%)	0 (0%)	0 (-)
3.	To consider and approve the profit distribution plan for 2022.	210,156,254 (100%)	0 (0%)	0 (-)
4.	To consider and approve the audited consolidated financial statements of the Company for 2022.	210,156,254 (100%)	0 (0%)	0 (-)
5.	To consider and approve the annual report of the Company for 2022.	210,156,254 (100%)	0 (0%)	0 (-)
6.	To authorize the Board to determine the remuneration of the Directors.	210,156,254 (100%)	0 (0%)	0 (-)
7.	To authorize the Board of Supervisors to determine the remuneration of the supervisors of Company.	210,156,254 (100%)	0 (0%)	0 (-)

Ordinary Resolutions		Number of Votes (Approximate % of the Total Number of Votes Cast)		
		For	Against	Abstain
8.	To consider and approve the re-appointment of Ernst & Young as the auditors of the Company for a term until the conclusion of the next annual general meeting of the Company and to authorize the Board to determine its remuneration.	203,595,266 (99.9999956%)	9 (0.0000044%)	6,560,977 (-) ^{Note}
9.	To consider and approve the appointment of Mr. LIU Wei (劉偉) as an executive Director.	210,156,254 (100%)	0 (0%)	0 (-)
As more than half of the votes were cast in favor of each of the resolutions numbered 1 to 9, all the above resolutions were duly passed as ordinary resolutions.				
Special Resolution		Number of Votes (Approximate % of the Total Number of Votes Cast)		
		For	Against	Abstain
10.	To grant a general mandate to the Board to allot, issue and/or otherwise deal with additional Shares (the full text of the resolution is set out in the Notice of the AGM).	210,156,254 (100%)	0 (0%)	0 (-)
As more than two-thirds of the votes were cast in favor of the resolution numbered 10, the resolution numbered 10 was duly passed as a special resolution.				

Note: Pursuant to the Articles of Association, an abstention, or an abstention from voting, shall not be counted in computing the result of that vote.

APPOINTMENT OF MR. LIU WEI AS EXECUTIVE DIRECTOR

The proposed resolution on the appointment of Mr. LIU Wei (劉偉) (“**Mr. Liu**”) as an executive Director was duly passed at the AGM. The Board is pleased to announce the appointment of Mr. Liu as an executive Director with effect from the conclusion of the AGM.

The biographical details and other information of Mr. Liu as required under Rule 13.51(2) of the Listing Rules are set out in the Circular. Save as disclosed in the Circular, as at the date of this announcement, Mr. Liu does not hold any other positions with the Group, nor did he hold any other directorships in the last three years in public companies the securities of which are listed on any securities markets in Hong Kong or overseas, major appointments or professional qualifications. Further, as at the date of this announcement, Mr. Liu has no relationship with any other Directors, Supervisors, senior management, substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company, nor does he have any interests in the Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board would like to take this opportunity to congratulate Mr. Liu on his new appointment.

By Order of the Board
Cryofocus Medtech (Shanghai) Co., Ltd.
Mr. LI Kejian
Chairman of the Board

Hong Kong, June 16, 2023

As at the date of this announcement, the Board comprises Mr. LI Kejian, Mr. ZHU Jun and Mr. LIU Wei as executive Directors, Mr. LV Shiwen and Mr. ZHAO Chunsheng as non-executive Directors, and Dr. GAO Dayong, Mr. LIANG Hsien Tse Joseph, Dr. QIN Zheng and Dr. HU Henan as independent non-executive Directors.